Turn Therapeutics grants 83,334 options to director
Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036.
The option award vests in twelve equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this grant, the reporting person holds 83,334 stock options directly.
Insider Trade Summary
Grant/Award: 83,334 shares
Grant/Award
1 txn
Insider
Kester Kent Edward
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 83,334 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 83,334 contracts (Direct)
Footnotes (1)
- F1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Key Figures
Options granted: 83,334 options
Exercise price: $5.75 per share
Expiration date: June 4, 2036
+2 more
5 metrics
Options granted
83,334 options
Stock option grant to director Kester Kent Edward
Exercise price
$5.75 per share
Stock option exercise price for Common Stock
Expiration date
June 4, 2036
Option term end date
Post-grant option holdings
83,334 options
Total options held directly after transaction
Vesting schedule
12 equal monthly installments
Vesting from June 30, 2026, subject to continued employment
Key Terms
Stock option (right to buy), Grant, award, or other acquisition, exercise price, 2025 Omnibus Incentive Plan, +1 more
5 terms
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "5.7500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2025 Omnibus Incentive Plan financial
"subject to ... the Issuer's 2025 Omnibus Incentive Plan"
An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.
vesting financial
"The option will vest in twelve (12) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Turn Therapeutics (TTRX) report for Kester Kent Edward?
Turn Therapeutics reported that director Kester Kent Edward received a grant of 83,334 stock options. These options relate to Common Stock, were awarded at a $5.75 exercise price, and represent a compensation-related acquisition rather than an open-market purchase or sale of shares.
What are the key terms of the 83,334 Turn Therapeutics (TTRX) stock options?
The 83,334 stock options have a $5.75 per share exercise price and expire on June 4, 2036. They are stock options to acquire Common Stock and were granted as compensation under Turn Therapeutics’ equity incentive framework for its director.
How do the new Turn Therapeutics (TTRX) options vest for Kester Kent Edward?
The options vest in twelve equal monthly installments, each on the last day of the month, starting June 30, 2026. Vesting is conditioned on Kester Kent Edward’s continued employment and compliance with the applicable option award and 2025 Omnibus Incentive Plan terms.
Under which plan were the Turn Therapeutics (TTRX) options granted?
The stock options granted to Kester Kent Edward were issued under Turn Therapeutics’ 2025 Omnibus Incentive Plan. This plan governs the terms, conditions, and vesting requirements of the award, including continued employment and other plan-specific provisions.
What is Kester Kent Edward’s option position in Turn Therapeutics (TTRX) after this grant?
After this transaction, Kester Kent Edward directly holds 83,334 stock options in Turn Therapeutics. These options are rights to buy Common Stock at $5.75 per share, subject to the specified vesting schedule and the 2036 expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
